Cargando…
Prophylactic or Early Use of Eculizumab and Graft Survival in Kidney Transplant Recipients With Atypical Hemolytic Uremic Syndrome in the United States: Research Letter
INTRODUCTION: Among kidney transplant recipients (KTRs) with end-stage kidney disease (ESKD) due to atypical hemolytic uremic syndrome (aHUS), recurrence is associated with poor allograft outcomes. We compared graft and patient survival of aHUS KTRs with and without prophylactic/early use of eculizu...
Autores principales: | Plasse, Richard A., Olson, Stephen W., Yuan, Christina M., Agodoa, Lawrence Y., Abbott, Kevin C., Nee, Robert |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8020226/ https://www.ncbi.nlm.nih.gov/pubmed/33868691 http://dx.doi.org/10.1177/20543581211003763 |
Ejemplares similares
-
Assessing the Impact of Prophylactic Eculizumab on Renal Graft Survival in Atypical Hemolytic Uremic Syndrome
por: Glover, Emily K., et al.
Publicado: (2023) -
Atypical Hemolytic Uremic Syndrome After Liver Transplant Treated With Eculizumab
por: Bhatti, Sundus, et al.
Publicado: (2020) -
Critical appraisal of eculizumab for atypical hemolytic uremic syndrome
por: Palma, Lilian M Pereira, et al.
Publicado: (2016) -
Atypical hemolytic uremic syndrome and eculizumab therapy in children
por: Kim, Seong Heon, et al.
Publicado: (2018) -
Treatment of Atypical Hemolytic-Uremic Syndrome in the Era of Eculizumab
por: Ebrahem, Rawaa, et al.
Publicado: (2017)